CSPC Pharmaceutical Group (1093) Price & Analysis

Compare

18 Followers

1093 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$4.27 - HK$11.63

Previous CloseN/A

Volume61.16M

Average Volume (3M)177.62M

Market Cap

$115.15B

Enterprise ValueHK$79.93B

Total Cash (Recent Filing)$8.25B

Total Debt (Recent Filing)$507.33M

Price to Earnings (P/E)28.5

Beta0.93

Next Earnings

Nov 26, 2025

EPS Estimate

0.14

Next Dividend Ex-Date

Oct 17, 2025

Dividend Yield2.6%

Share Statistics

EPS (TTM)0.09

Shares Outstanding11,522,452,000

10 Day Avg. Volume175,062,117

30 Day Avg. Volume177,619,873

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.69

Enterprise Value/Revenue2.59

Enterprise Value/Gross Profit3.70

Enterprise Value/Ebitda11.95

Forecast

1Y Price Target

$9.72

Price Target Upside-2.87% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Business Development DealsTwo additional large-scale BD deals are expected, each anticipated to exceed US$5 billion, indicating strong future revenue potential.

Product Sales RecoveryManagement anticipates a recovery in product sales with expected growth of at least 5%.

Bears Say

Oncology Revenue DropInventory destocking in oncology products continues, with a sharp fall in oncology revenue mainly due to significant price cuts.

Sales DeclineSales of finished drugs declined, driven by a decrease in CNS products due to channel compensation following NRDL price cuts.

CSPC Pharmaceutical Group News

CSPC Pharmaceutical Advances Parkinson’s Treatment with New Clinical Trial Approval

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Pharmaceutical Group announced that its subsidiary, AlaMab...

3d ago

CSPC Pharmaceutical Gains Approval for Clinical Trials of Innovative RSV Drug

CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an update. CSPC Pharmaceutical Group Limited has announced that its...

6d ago

CSPC’s KN026 Drug Application Accepted by NMPA

CSPC Pharmaceutical Group ( ($HK:1093) ) has provided an update. CSPC Pharmaceutical Group announced that its new drug...

7d ago

CSPC Pharmaceutical Group Reports Decline in 2025 Interim Results

CSPC Pharmaceutical Group ( ($CHJTF) ) has released its Q2 earnings. Here is a breakdown of the information...

27d ago

CSPC Pharmaceutical’s Cancer Drug SYS6036 Approved for Clinical Trials in China

An announcement from CSPC Pharmaceutical Group ( ($HK:1093) ) is now available. CSPC Pharmaceutical Group announced that its...

27d ago

CSPC Pharmaceutical Group Reports Decline in 2025 Interim Results Amid Strategic Focus on Innovation

CSPC Pharmaceutical Group ( ($HK:1093) ) just unveiled an announcement. CSPC Pharmaceutical Group reported a significant decline in...

28d ago

CSPC Pharmaceutical Group Declares Interim Dividend for 2025

CSPC Pharmaceutical Group ( ($HK:1093) ) just unveiled an update. CSPC Pharmaceutical Group has announced an interim dividend...

28d ago

CHJTF Earnings this Week: How Will it Perform?

CSPC Pharmaceutical Group (CHJTF) is scheduled to report 2nd quarter earnings on 08/22/2025. Regarding Q2 estimates, Wall Street...

29d ago

CSPC Pharmaceutical Group’s Dupilumab Injection Approved for Clinical Trials in China

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an update. CSPC Pharmaceutical Group has announced that its Dupilumab...

1M ago

CSPC Innovation Reports Revenue Growth Amidst Profitability Challenges

CSPC Pharmaceutical Group ( ($HK:1093) ) has issued an announcement. CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of...

1M ago

1093 FAQ

What was CSPC Pharmaceutical Group Limited’s price range in the past 12 months?

CSPC Pharmaceutical Group Limited lowest stock price was HK$4.27 and its highest was HK$11.63 in the past 12 months.

What is CSPC Pharmaceutical Group Limited’s market cap?

CSPC Pharmaceutical Group Limited’s market cap is $115.15B.

When is CSPC Pharmaceutical Group Limited’s upcoming earnings report date?

CSPC Pharmaceutical Group Limited’s upcoming earnings report date is Nov 26, 2025 which is in 69 days.

How were CSPC Pharmaceutical Group Limited’s earnings last quarter?

CSPC Pharmaceutical Group Limited released its earnings results on Aug 22, 2025. The company reported HK$0.093 earnings per share for the quarter, missing the consensus estimate of HK$0.146 by -HK$0.053.

Is CSPC Pharmaceutical Group Limited overvalued?

According to Wall Street analysts CSPC Pharmaceutical Group Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CSPC Pharmaceutical Group Limited pay dividends?

CSPC Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.14 which represents an annual dividend yield of 2.6%. See more information on CSPC Pharmaceutical Group Limited dividends here

What is CSPC Pharmaceutical Group Limited’s EPS estimate?

CSPC Pharmaceutical Group Limited’s EPS estimate is 0.14.

How many shares outstanding does CSPC Pharmaceutical Group Limited have?

CSPC Pharmaceutical Group Limited has 11,522,452,000 shares outstanding.

What happened to CSPC Pharmaceutical Group Limited’s price movement after its last earnings report?

CSPC Pharmaceutical Group Limited reported an EPS of HK$0.093 in its last earnings report, missing expectations of HK$0.146. Following the earnings report the stock price went up 0.191%.

Which hedge fund is a major shareholder of CSPC Pharmaceutical Group Limited?

Currently, no hedge funds are holding shares in HK:1093

CSPC Pharmaceutical Group Stock Smart Score

Outperform

Fundamentals

Return on Equity

11.30%

Trailing 12-Months

Asset Growth

-2.61%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CSPC Pharmaceutical Group Limited

CSPC Pharmaceutical Group (1093) is a leading pharmaceutical company based in China, engaged in the development, manufacture, and sale of pharmaceutical products. The company operates across several key sectors, including innovative drug development, generic drugs, and bulk drugs. CSPC focuses on various therapeutic areas such as oncology, cardiovascular, and central nervous system disorders, offering a diverse portfolio of products that cater to both domestic and international markets.

CSPC Pharmaceutical Group (1093) Earnings & Revenues

Historic Earnings Reports

1093 Stock 12 Month Forecast

Average Price Target

HK$9.72

▼(-2.87% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"HK$3","8":"HK$8","13":"HK$13","5.5":"HK$5.5","10.5":"HK$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12.90140479862349,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$12.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.723162125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$9.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.0005444955905,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.5,8,10.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.99,11.137031138355653,11.284062276711307,11.43109341506696,11.578124553422613,11.725155691778266,11.872186830133918,12.019217968489572,12.166249106845225,12.313280245200879,12.460311383556531,12.607342521912184,12.754373660267838,{"y":12.90140479862349,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.99,10.892550932692307,10.795101865384616,10.697652798076923,10.60020373076923,10.50275466346154,10.405305596153847,10.307856528846154,10.21040746153846,10.11295839423077,10.015509326923077,9.918060259615384,9.820611192307693,{"y":9.723162125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.99,10.529272653506961,10.068545307013924,9.607817960520885,9.147090614027846,8.686363267534809,8.22563592104177,7.7649085745487305,7.304181228055692,6.843453881562654,6.382726535069615,5.921999188576577,5.461271842083539,{"y":5.0005444955905,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.008,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.546,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.815,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.202,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.718,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.422,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.649,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.051,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.611,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >